Docetaxel

(asked on 23rd October 2017) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, how much has been spent by each clinical commissioning group in England on Docetaxel since the publication of Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naive metastatic prostate cancer by NHS England on 20 January 2016.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 1st November 2017

There were no prescriptions of docetaxel by clinical commissioning groups in primary care over this period.

NHS Digital is unable to identify the specific indication for which a prescription has been prescribed. Information on hospital costs (at list price) covering all possible uses is available at NHS England Region level and is provided in the table below:

National Health Service estimated costs (£) of docetaxel (at list price) issued by hospital pharmacies in England1, by region, 2015 and 2016

2015

2016

England1

64,346,509

71,385,551

Central Midlands

4,681,236

5,933,700

Cheshire and Merseyside

4,725,933

4,126,694

Cumbria and North East

3,020,396

3,571,486

East

5,375,050

5,603,733

Greater Manchester

3,349,575

2,833,002

Lancashire

1,528,395

1,718,229

London

8,746,042

10,175,348

North Midlands

4,125,206

5,538,382

South Central

3,269,040

4,113,010

South East

6,448,259

6,182,164

South West

3,924,561

4,038,755

Wessex

3,325,580

4,016,453

West Midlands

5,432,613

6,522,771

Yorkshire and Humber

5,825,101

6,429,341

Source: 2017 QuintilesIMS: Hospital Pharmacy Audit Index;

Note:

1National figures are grossed up to give England level estimates. Sub-national figures are not adjusted in any way. Therefore, the sum of the regions will not match the England total.

Reticulating Splines